Intellipharmaceutics (IPCI) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Maxim Affirms Intellipharmaceutics (IPCI) at 'Buy' Following Q3 Results; Says Rexista NDA is Next Big Event
October 14, 2016 12:09 PM EDTMaxim reaffirms Intellipharmaceutics International (Nasdaq: IPCI) at Buy with a price target of $6 following Q3 results issued Thursday night.
Jason Kolbert noted the following on Friday:
Licensing agreement. Intellipharmaceutics recently announced a commercial supply agreement with Mallinckrodt ($3M... More